Brainstorm Cell Therapeutics Inc's NurOwn Cell Therapy Receives Orphan Drug Designation In European Union For Als


Monday, 29 Jul 2013 08:32am EDT 

BrainStorm Cell Therapeutics Inc announced that the European Commission has granted Orphan Drug Designation for NurOwn, the Company's stem cell therapy consisting of autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors, for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. NurOwn received Orphan Drug Designation from the Food and Drug Administration (FDA) in 2011. 

Company Quote

0.351
-0.012 -3.31%
11 Jul 2014